# OnCo record ravulizumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ravulizumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ravulizumab" ;
  schema:name "Ravulizumab"@en ;
  schema:alternateName "Ravulizumab-cwvz"@en, "ALXN1210"@en, "Ultomiris" ;
  schema:description "Ravulizumab is an eight-weekly infusion that blocks the complement system; it treats paroxysmal nocturnal haemoglobinuria, a clonal bone marrow disorder managed by haematologists alongside aplastic anaemia and myelodysplasia."@en ;
  schema:url <https://onco.cc/drugs/ravulizumab/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ravulizumab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ravulizumab>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761108> ;
  onco:status "established" ;
  onco:tag "gap-fill", "supportive-care" ;
  onco:modality "Long-acting anti-complement C5 monoclonal antibody" ;
  onco:approval "US 2018: Paroxysmal nocturnal haemoglobinuria" ;
  onco:cancers <https://onco.cc/cancers/mds/> ;
  onco:technologies <https://onco.cc/fronts/supportive-care/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .